The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Newron has randomised the first participants in its ENIGMA-TRS 1 Phase III programme of evenamide for treatment-resistant ...

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

The FDA has given the green light for Tiziana Life Sciences’ IND to advance its Phase IIa study of intranasal foralumab for MSA.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome treatment.

The cancer vaccine did not significantly boost progression-free survival (PFS), but IO Biotech plans to seek out its approval anyway.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with advanced head and neck cancers.

Palisade Bio has reported positive outcomes from the Phase Ib open-label cohort of PALI-2108 in those with moderate-to-severe UC.

After the success of the Phase Ib study, Assembly Bio’s herpes therapy will advance to Phase II trials in mid-2026.